Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers
Open Access
- 11 October 2017
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 17 (3) , 200-210
Abstract
Breast cancer metastasis is a highly prevalent cause of death for European females. DNA microarray analysis has established that primary tumors, which remain localized, differ in gene expression from those that metastasize. Crossanalysis of these studies allow to revile the differences that may be used as predictive in the disease prognosis and therapy. The aim of the project was to validate suggested prognostic and therapeutic markers using meta-analysis of data on gene expression in metastatic and primary breast cancer tumors. Data on relative gene expression values from 12 studies on primary breast cancer and breast cancer metastasis were retrieved from Genevestigator (Nebion) database. The results of the data meta-analysis were compared with results of literature mining for suggested metastatic breast cancer markers and vectors and consistency of their reported differential expression. Our analysis suggested that transcriptional expression of the COX2 gene is significantly downregulated in metastatic tissue compared to normal breast tissue, but is not downregulated in primary tumors compared with normal breast tissue and may be used as a differential marker in metastatic breast cancer diagnostics. RRM2 gene expression decreases in metastases when compared to primary breast cancer and could be suggested as a marker to trace breast cancer evolution. Our study also supports MMP1, VCAM1, FZD3, VEGFC, FOXM1 and MUC1 as breast cancer onset markers, as these genes demonstrate significant differential expression in breast neoplasms compared with normal breast tissue. COX2 and RRM2 are suggested to be prominent markers for breast cancer metastasis. The crosstalk between upstream regulators of genes differentially expressed in primary breast tumors and metastasis also suggests pathways involving p53, ER1, ERB-B2, TNF and WNT, as the most promising regulators that may be considered for new complex drug therapeutic interventions in breast cancer metastatic progression.Keywords
This publication has 87 references indexed in Scilit:
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancerBMC Cancer, 2008
- Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteinsJournal of Cellular Biochemistry, 2007
- Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?Nature Reviews Cancer, 2007
- The Forkhead Box M1 Protein Regulates the Transcription of the Estrogen Receptor α in Breast Cancer CellsJournal of Biological Chemistry, 2006
- Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancerBreast Cancer Research and Treatment, 2005
- Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastasesJournal of Cancer Research and Clinical Oncology, 2004
- Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinomaEuropean Journal of Cancer, 2002
- The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.1996
- Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1.1993